A territory-wide real-world efficacy and toxicity analysis of abiraterone acetate versus docetaxel in 574 Asian patients with metastatic hormone-sensitive prostate cancer
-
Published:2023-08
Issue:
Volume:
Page:
-
ISSN:1558-7673
-
Container-title:Clinical Genitourinary Cancer
-
language:en
-
Short-container-title:Clinical Genitourinary Cancer
Author:
LAM Benjamin H.W.,
TSANG Vivian H.M.ORCID,
LEE M.P.,
CHAN Kuen,
LIU Tsz ChimORCID,
NG Brian Y.H.,
WO Barry B.W.,
LEUNG K.C.,
MUI Wing Ho,
CHAN Tim Wai,
LAM Martin Ho Ching,
SIU Steven W.K.,
POON Darren M.C.ORCID
Reference30 articles.
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA Cancer J Clin,2021
2. Epidemiology and genomics of prostate cancer in Asian men;Zhu;Nat Rev Urol,2021
3. Metastatic hormone-sensitive prostate cancer (mHSPC): advances and treatment strategies in the first-line setting;Ng;Oncol Ther,2020
4. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer;Sweeney;N Engl J Med,2015
5. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial;James;Lancet,2016
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献